Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

BACKGROUND: Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β(2−)agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and tolerability of single doses of navafenterol were investigated in patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Singh, Dave, Balaguer, Victor, Astbury, Carol, Wählby-Hamrén, Ulrika, Jimenez, Eulalia, Seoane, Beatriz, Villarroel, Cristina, Lei, Alejhandra, Aggarwal, Ajay, Psallidas, Ioannis
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7487995/
https://ncbi.nlm.nih.gov/pubmed/32907566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-01347-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados